| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Tax liability | $1,395,179 | -29,767 | -8.4% | $46.87 | 323,862 | 23 Feb 2022 | Direct | F1 |
| holding | PFE | Common Stock | 1,817 | 23 Feb 2022 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +126,794 | $0.000000 | 126,794 | 24 Feb 2022 | Common Stock | 126,794 | $45.96 | Direct | F2 | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +111,516 | $0.000000 | 111,516 | 24 Feb 2022 | Common Stock | 111,516 | $45.96 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). |
| F2 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| F3 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |